The common AEs observed in this study were increased AST or ALT levels, thrombocytopenia, anemia, neutropenia, leukocytopenia, abnormal ECG, vomiting, nausea, and fatigue, which were similar to those reported in a previous study of chemotherapy and an anti-PD-1 antibody.8 Hematologic toxicity was the main grade 3 or higher AE in this study as well as the most common TEAE for toripalimab in a phase 3 study on advanced nasopharyngeal carcinoma.34 In the present study, dose modification was observed in six subjects and medication delay in ten subjects due to AEs. Here, GPT is linked to neutropenia.